PTPA and prostate carcinoma: Treatment with the PP2A activators forskolin and FTY720 reduced prostasphere formation capability of two prostate cancer cell lines, PC-3 and LNCaP; however, pretreatment with the PP2A inhibitor, okadaic acid, partially quenched the forskolin- and FTY720-induced antitumor effects.